Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 4, 2013, by Jazz Pharmaceuticals Plc. The filing presents unaudited pro forma condensed combined statements of operations for the year ended December 31, 2012. The report specifically addresses the financial impact of two major transactions consummated during 2012: the Azur Merger and the EUSA Acquisition.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references Exhibit 99.1, which contains the unaudited pro forma condensed combined statement of operations giving effect to the aforementioned transactions. No standalone financial metrics are disclosed within the body of this report.
Material Changes and Transactions
- Azur Merger: Completed on January 18, 2012, between Azur Pharma Public Company Limited and Jazz Pharmaceuticals, Inc. (JPI). For accounting purposes, this was treated as a reverse acquisition where JPI was the accounting acquirer, and JPI's financial statements became the historical financial statements of the Company.
- EUSA Acquisition: Completed on June 12, 2012, involving the acquisition of EUSA Pharma, Inc.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies. Its sole purpose is to disclose the pro forma financial information related to the 2012 transactions.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012.
- Verify the accounting treatment of the Azur Merger as a reverse acquisition and its impact on historical financial reporting.
- Confirm the integration of EUSA Pharma, Inc. into the Company's financial results as of June 12, 2012.